ArticleTranslational oncology2011
Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.
Article in Translational oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.Molecules (Basel, Switzerland) · 2019Article
- Quantitative Proteomics and Metabolomics Reveal Biomarkers of Disease as Potential Immunotherapy Targets and Indicators of Therapeutic Efficacy.Theranostics · 2019Review
- Selective depletion of metastatic stem cells as therapy for human colorectal cancer.EMBO molecular medicine · 2018Article
- Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches.Chembiochem : a European journal of chemical biology · 2018Article
- Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.BMC cancer · 2017Article
- Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met.Nature medicine · 2015Article
- Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance.Analytical cellular pathology (Amsterdam) · 2015Review
- Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Current molecular medicine · 2013Review
- Genomic analysis of the ecdysone steroid signal at metamorphosis onset usingGenes & genomics · 2013Article
- Article
- Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.American journal of nuclear medicine and molecular imaging · 2012Article
- Article
- Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.Molecular pharmaceutics · 2011Article
- Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.Bioconjugate chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathology is fundamental in grading, staging, and treatment planning of malignancies. One relatively novel biomarker that may become more important in therapy and diagnostics is the chemokine receptor 4 (CXCR4). Ac-TZ14011 peptide derivatives, functionalized with a radiolabel, can be used for molecular imaging of tumors. Direct fluorescent labeling of the small peptide Ac-TZ14011 with the fluorescent dye fluorescein isothiocyanate (FITC), however, provides an alternative for the detection of CXCR4 expression levels in cells and tumor tissue. In this study, Ac-TZ14011-FITC was validated for CXCR4 staining in human breast cancer cell lines MDAMB231 and MDAMB231(CXCR4+) during flow cytometric analysis. Its efficacy was compared to commercially available antibodies. Competition experiments validated the staining specificity. Confocal imaging revealed that CXCR4 staining was predominantly found on the cell membrane and/or in vesicles formed after endocytosis. Next to being able to differentiate "high" and "low" CXCR4-expressing tumor cells, the fluorescent peptide demonstrates potential in fluorescent immunohistochemistry of tumor tissue. Ac-TZ14011-FITC was able to differentiate MDAMB231 from MDAMB231(CXCR4+) tumor cells and tissue, proving its applicability in the detection of differences in CXCR4 expression levels.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.